Therapeutic Asset Ratings
748 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Pep-Dc1
Ovarian Carcinoma
Centre Hospitalier Universitaire Vaudois
P1/2
CC
(45)
Pep-Dc2
Ovarian Carcinoma
Centre Hospitalier Universitaire Vaudois
P1/2
CC
(45)
tg01
Smoldering Plasma Cell Myeloma
Oslo University Hospital
P1/2
CC
(45)
bnt162b2
Multiple Sclerosis
Griffin Hospital
P2
CC
(44)
Pvx-410
Smoldering Plasma Cell Myeloma
Massachusetts General Hospital
P1
CC
(44)
il15-transpresenting wt1-targeted dendritic cell vaccine
Esophageal Cancer
University Hospital, Antwerp
P1/2
CC
(44)
il15-transpresenting wt1-targeted dendritic cell vaccine
Liver Cancer
University Hospital, Antwerp
P1/2
CC
(44)
Personalized Neoantigen Peptide Vaccine
Solid Tumor, Adult
Seqker Biosciences, Inc.
P1/2
CC
(44)
Tozinameran
Acute Leukemia
Assistance Publique - Hôpitaux de Paris
P1/2
CC
(44)
bnt162b2
Juvenile Dermatomyositis
National Institute of Allergy and Infectious Diseases (NIAID)
P2
CC
(43)
bnt162b2
Juvenile Idiopathic Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)
P2
CC
(43)
bnt162b2
Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)
P2
CC
(43)
bnt162b2
Pediatric Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)
P2
CC
(43)
bnt162b2
Pediatric Systemic Lupus Erythematosus
National Institute of Allergy and Infectious Diseases (NIAID)
P2
CC
(43)
bnt162b2
Pemphigus Vulgaris
National Institute of Allergy and Infectious Diseases (NIAID)
P2
CC
(43)
bnt162b2
Rheumatoid Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)
P2
CC
(43)
bnt162b2
Systemic Lupus Erythematosus
National Institute of Allergy and Infectious Diseases (NIAID)
P2
CC
(43)
bnt162b2
Systemic Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)
P2
CC
(43)
SEVIPROTIMUT-L
Peripheral T Cell Lymphoma
Affimed GmbH
P2
CC
(43)
SEVIPROTIMUT-L
Relapsed or Refractory Hodgkin Lymphoma
Affimed GmbH
P2
CC
(43)
abo2102
Advanced / Metastatic Solid Tumor
Suzhou Abogen Biosciences Co., Ltd.
P1
CC
(43)
ad5.f35-hgucy2c-padre vaccine
Small Intestine Adenocarcinoma
Thomas Jefferson University
P1
CC
(43)
ak154
Pancreatic Ductal Adenocarcinoma
Akeso
P1
CC
(43)
Ast-201
Liver And Intrahepatic Bile Duct Neoplasm
Aptamer Sciences, Inc.
P1
CC
(43)
Autologous Neoantigen-Pulsed Dendritic Cell Vaccine
Castration-Resistant Prostate Carcinoma
Changhai Hospital
P1
CC
(43)
Showing 426 to 450 of 748 assets
Previous
Page 18 of 30
Next
